A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Exploiting receptor tyrosine kinase co-activation for cancer therapy
2017
Drug Discovery Today
Studies over the past decade have shown that Receptor Tyrosine Kinase (RTK) co-activation is prevalent in many cancer types. Compelling data demonstrates that cancers are likely to have evolved RTK co-activation as a generic means for driving tumour growth and providing a buffering system to limit the lethal effects of microenvironmental insults including therapy. In this review, we summarise the general principles of RTK co-activation gleaned from key studies over the last decade. We discuss
doi:10.1016/j.drudis.2016.07.010
pmid:27452454
pmcid:PMC5346155
fatcat:lv2owxvdofanfc6p2la5wpa4yy